Thank you for standing by, and welcome to the Harvard Bioscience Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star one one on your telephone. If your question has been answered and you'd like to remove yourself from the queue, please press star one one again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Dave Sirois, Director of SEC Reporting. Please go ahead, sir. Thank you, Jonathan, and good morning, everyone. Thank you for joining the Harvard Bioscience Third Quarter 2023 Earnings Conference Call. Before we begin, I would like to suggest that you take a moment and download a copy of a presentation that will be referred to during this call. The file is entitled Q3 2023 HBIO Quarterly Earnings Presentation and is located in the Investor Overview, Events, and Presentation section of our website. Leading the call today will be Jim Green, Chairman of the Board, President, and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer. Before I turn the call over to Jim, I will read our safe harbor statement. In our discussion today, we may make statements that constitute forward-looking statements. Our actual results and performance may differ materially from what we have projected due to risks and uncertainties, including those described in our annual report on Form 10-K for the period ended December 31, 2022, our subsequent quarterly reports on Form 10-Q, and our other public filings. Any forward-looking statements, including those related to the company's future results and activities, represent our estimates as of today and should not be relied upon as representing our estimates as of any subsequent day. Also, much of today's call will focus on our non-GAAP quarterly results, which we believe better represent the ongoing economics of the business, reflects how we set and measure our incentive compensation plans, and how we manage the business internally. The difference between our GAAP and non-GAAP results are outlined in the earnings release in today's presentation. These two documents, as well as a replay of this call, can be found on our website under Investor Overview, Events, and Presentations. Additionally, any material, financial, or other statistical information presented on the call, which is not included in our press release and presentation, will be archived and available in the Investor Relations section of our website. I will now turn the call over to Jim. Jim, please go ahead. Thank you, David. Hello, everybody. Let's start by moving to slide three of the presentation and take a look at the highlights for the quarter. First, I'll say that I'm pleased to see strong growth in North America. However, similar to numerous lifecycle tools companies, we did see. We were impacted by post-COVID lower demand in China and Asia Pacific. Going to the numbers, revenue for the quarter was $25.4 million. That's down 6% from last year on an as-reported basis. This revenue includes a net effect of $1.3 million of discontinued products compared to the prior year period. Q3 revenue saw a net positive FX effect of $700,000. Adjusting for both FX and discontinued products, our underlying core revenue was down roughly 3.5%. Gross margin improved to $14.7 million, or 58% of revenue, up from 45% in the same period of FY 2022. However, this prior period included inventory write-down that impacted FY 2022 comparable by about 5%. Adjusted operating profit improved $1.8 million or 7.3% of revenue, up from $700,000 last year, an improvement of $1.1 million or nearly five percentage points. Adjusted EBITDA measured $2.2 million or 8.9% of revenue, also up five percentage points from the prior year. GAAP earnings per share was a $0.03 loss, an improvement from an $0.08 loss last year. Adjusted EPS measured a positive $0.01 per share, up from a $0.01 loss last year. Cash flow from operations was $4.4 million, versus $600,000 last year. In the appendix, you'll find the bridge from GAAP measurements to adjusted or non-GAAP measurements. Now, let's move to the next slide, slide four, and look at the revenue by quarter, by product family, and with an improved regional view. Starting with the Americas, revenue was up 5.9% as reported, and included 5.2% of net reduction of discontinued products. Considering discontinued, our underlying core revenue grew by about 11%. Preclinical had strong growth in our core tech telemetry and Ponemah Enterprise software, though somewhat held back by post-COVID, lower needs for respiratory products. Cellular molecular products were down primarily on discontinued low-margin products and some slowness in cell-based testing systems. Moving to EMEA. Overall, EMEA revenue was down 1.4% as reported and included a 6.2% net reduction from discontinued products, but also had a positive FX impact of 7.7%. Adjusting for FX and discontinued, EMEA was down roughly 3.5%. Now moving to China and Asia Pacific, Q3 reported revenue was down 30%. FX and discontinued products had a modest negative effect of approximately 4.5%. The primary impacts were twofold. Preclinical saw a big drop in demand in preclinical respiratory products, where during the COVID years, including 2022, China had significantly purchased for COVID research. However, our core telemetry and Ponemah Enterprise software held close to flat. CMT saw a measurable drop in cellular molecular products, where again, during COVID, China had strong demand in academic research. We move to slide five of the presentation, let me tell you a little bit about some of our exciting new products and new introductions that we'll be showing and showcasing, this next week at the Society for Neuroscience Conference. As you know, over the last three years, we've optimized our product offerings to target key technologies in the drug and therapy development continuum. Our product strategy is to continue to introduce new technologies and applications in leading academic research labs and pharma discovery, while at the same time adapting these technologies to further penetrate larger industrial applications with our customers in pharma and CROs and biotech. Following this strategy, next, we will be showcasing a number of these offerings, and I'll talk a little bit to you about three in particular here. First, we'll be highlighting our new Mesh Microelectrode Array platform. This new Mesh MEA, this, these new Mesh MEAs are targeted for use in organoids, which are small tissue segments or cultures that we believe can represent a proxy for many organs, such as brain and heart. Organoids are a promising growth area for academic research and discovery, as well as safety pharmacology and toxicology. Our new Mesh MEAs build on our recognized leadership position in single-well, high-density microelectrode arrays used heavily today, enabling precise signal measurement from within the organoid. We're excited to be presenting early research results using this novel technology on brain organoids at next week's Society for Neuroscience. Next, we'll highlight our new VivaMARS high-capacity behavior monitoring system. We first announced our initial customer order last April. The VivaMARS system is specifically adapted to high-volume, multi-animal model in vivo testing and formal reporting required for preclinical regulatory clearance. VivaMARS leverages our industry-leading Ponemah software platform, as well as our Panlab activity monitoring expertise. It is an excellent example of how we're able to leverage our expertise across all of Harvard Bioscience family. This system was developed with our CRO and pharma customer needs in mind and also meets their business needs to increase operating efficiencies, lowering costs, and more importantly, reducing test cycle times to expand capacity and support their revenue growth. We're expecting our first VivaMARS shipment to a CRO customer later in this year. Finally, we'll be showcasing our new SoHo small animal model telemetry platform. SoHo is based on our industry-leading telemetry and Ponemah Enterprise software platform and extends our leadership position with expanded capabilities, such as concurrent multi-model testing in a more natural shared housing environment. As with VivaMARS, this platform is designed to meet customers' challenging business needs for lowering operating costs and shorter test cycle times to expand test capacity and drive more of their revenue growth. Now I'll turn the call over to Jennifer, our CFO, for a look at key financials. Jennifer? Thank you, Jim. Let's jump into our Q3 financial results in greater detail, and if you can, please refer to slide 7. As a reminder, in addition to our reported GAAP results, we also include discussion about our adjusted or non-GAAP financial results, which align with information we use to internally manage the business. Our slide deck includes a reconciliation between our adjusted results and the corresponding GAAP financial measures on slide 11. Jim has already taken you through our revenue performance, and I'll take you through some of our other key financial metrics in more detail. If you can, please refer to the top middle of the slide. On a reported basis, our Q3 gross margin was 58.1%, compared to 45.2% in Q3 FY 2022. I would like to point out two factors that impacted our gross margin results for the quarters. A reminder that last quarter, we mentioned that we aligned our global process for capitalizing our inventory overhead costs. This had an unfavorable impact to gross margin during this quarter of approximately one percentage point. We do expect the roll-off of that change to complete during the middle of Q4. Additionally, last year, our Q3 gross margin was unusually low as a result of an inventory charge of $1.3 million related to the discontinuance of non-strategic products, which impacted last year unfavorably by about five percentage points. Taking into account both of these impacts, we are seeing substantial improvement in our gross margins, with underlying gross margin improvement by about 9% over the prior year quarter. Please refer now to the top right graph, where we'll discuss operating expenses and adjusted EBITDA. Our adjusted EBITDA during Q3 was $2.2 million, compared to $1 million last year. Our reported operating expenses were slightly reduced during the quarter compared to last Q3. We continue managing our overall operating expenses, with this year's OpEx reflecting merit increases and bonus accruals for our employees. Please refer to the bottom left, where we will show both reported and adjusted loss earnings per share. On a reported basis, we improved our diluted loss per share for the quarter from a loss of $0.08 to a loss of $0.03. On an adjusted basis, Q3 showed diluted earnings per share of $0.01, compared to a loss of $0.01 in Q3 of last year. We saw strong improvements due to the combined flow-through of our stronger margin dollars and lower operating expenses. When looking at last Q3, our results included a restructuring charge and inventory write-offs, which together were $2 million, which are excluded from our adjusted reporting. Income tax expense during the quarter related to adjusting our provisions for state and foreign jurisdictions, adjustments to our valuation reserves, and the normal annualization of our forecasted taxable income by entity. The provision recorded this quarter resulted in an unfavorable impact to our reported EPS of approximately $0.02. Now, if we switch gears to highlights on cash flow and liquidity, please refer to the graph in the middle of the bottom row, where we show another solid quarter with $4.4 million in cash flow from operations, as compared to $600,000 last Q3. This enabled us to pay down an additional $2.8 million against our credit facility during the quarter, bringing our year-to-date pay down to $8.3 million. Net debt at third quarter end, compared to prior year, is down $11 million. These improvements position us to achieve our targeted debt reduction goals for the year. We've typically run lean on capital investments, but we do expect to see increases in CapEx, primarily to support investments in tooling and equipment for our new product introductions as we enter 2024. Further details on the above items are available in our 10-Q and non-GAAP reconciliation tables included in our press release and in the appendix to this presentation. I'm now happy to hand back to Jim to cover 2023 guidance. Thank you, Jen. Now, moving to our summary on slide 9, let's take a look at what we see for the full year 2023. We now expect 2023 full year reported revenue to be roughly flat compared to prior year, and that includes five percentage points of discontinued products as compared to prior year. We expect gross margin to remain strong in the 60% range. We expect adjusted EBITDA margins in the 13%-14% range. We expect our improved EBITDA and cash flow from operations to support significant debt paydown in FY 2023. We continue to reduce net leverage to approximately the 2x level by the end of 2023. I think it's important to know that overall, our core business remains strong, and this team continues to focus on exciting new product introductions and expanding service offerings to fuel new growth and a bright future. Thank you. Now, I'll turn the call over to Jonathan, our operator, to open the line for questions. Thank you. Thank you. Ladies and gentlemen, once again, if you have a question at this time, please press star one one on your telephone. One moment for our first question. Our first question comes from the line of Bruce Jackson from Benchmark. Your question, please. Hi, good morning, and thanks for taking my question. First, on the gross margins, nice job. I wanted to know, how sustainable do you think those are going forward, and could we see any further expansion in 2024? Good. Hi, Bruce. Great question. You know, we've been focusing on our overall cost of operations. We're, we're confident that, and as we had said, that this year, we would move toward that roughly 60% region. We think we're gonna get within spitting distance of that this year. So we expect that, you know, going forward, we're gonna, we're gonna be not, not just where we are today, but even better, as, as Jen said. You know, we've, we've made some modifications to, how we handle, you know, various accounting structures, and that has had a bit of a negative effect. And in spite of that, we still were looking at, you know, 58%+ gross margin in a quarter that really wasn't all that strong from a revenue perspective. So as we look forward, you know, certainly as we look into Q4 and going forward, you know, our goal's always been to get at 60% or better. So going into next year, I'm confident that we're gonna be at that 60% or better kind of number on the gross margin side. Okay, great. And then, a two-part follow-up question on China. Can you maybe give us a little color on the underlying demand for the products in China from the academic research side? And, you know, is that going to bounce back at any point? And then, secondly, can you give us just a sense of the degree of exposure that that particular region has to the respiratory research business, and is it coming back? Yeah, that's a great question. We you know, in China and Asia Pacific is where we saw pretty strong demand for the new respiratory products during the entire COVID phase. And, you know, they probably, at this point, you know, I would believe that they maybe bought more than they need, you know. They, and at this point, given moving forward without the amount of COVID research that was taking place, we're probably gonna see more at this slightly lower level on the respiratory product. You know, that's not a great big part of our product line, you know, but it, it's measurable for us. So when I think of the two primary things that, you know, held us back in this quarter, and really we started seeing it potentially starting last quarter, and then, you know, it's likely to go into Q4, is really limited to these respiratory products in China, and then this kind of general slowing that we saw across the CMT line. And that, again, is highly likely, we believe, to be the fact that a lot of things were purchased at a higher level during, you know, 2020, 2021, 2022, especially in Asia. Because many of those products were targeted to finding solutions to COVID, you know, things like products like our, you know, cell-based testing products and electroporation and transfection products. So and much of that did go in, was in academic research. So I think for your second question, you know, academic research, you know, we, there's the outlook is that it's gonna get back to a normalized number. How fast it gets. Will it get back at or above these COVID numbers is, you know, I certainly wouldn't bet on that. But I think if nothing else, we'll at least, you know, move to a good, stable base and start to grow off of that. You know, it's anybody's guess what the government's gonna do there as far as, you know, some of these new funding methods that they've been—we've been hearing about. We're certainly looking forward to it. You know, but again, I think it, it's good news to just to be able to feel like the two primary headwinds for us has been really associated with post-COVID and China, and limited to a fairly small number of products. Thank you. Thanks, Bruce. Thank you. One moment for our next question. Our next question comes from the line of Frank DiLorenzo from Singular Research. Your question, please. Good morning, and thanks for taking my call. Following on. Hi, Frank. Hi, how are you? Following on with the China question, could you talk about interest you might be seeing for some of your newer product offerings, the organoid space and elsewhere, and if you have any visibility on that going forward? And then I'll have a follow-on. Thanks. Okay. Well, I think, you know, with SfN, that's our biggest show, Society for Neuroscience. Perfect timing for us with a number of our very key core business products. You know, our telemetry products, you know, we're expanding the offerings there. You know, I'm-- we're pretty certain that organoids is gonna get a lot of press. It's, it's been something that's been kind of brewing in academic research for a while. We've been investing pretty heavily over the last few years to turn this into something more than just an academic research product, but a real, you know, industrial-level use product. So I think we're, we're gonna learn a lot there. And then with the introduction of the new VivaMARS product, that's already getting a lot of interest worldwide, both in, you know, North America, Europe, and Asia. You know, every place that does, you know, that does, the formal in vivo testing for, with the behavioral requirements that are required for any, any product, you need to get to this kind of level of product, and you need to have, you know, high volume, high capacity, and it needs to be in a GLP environment. So we're real excited about VivaMARS. We see that, developing very quickly. We've already sold the first one. We'll be shipping it, shipping the very first unit, here, next month. And that, as we've said publicly, is, is about $850,000 system. That's just for one, to one customer, and we see this as, as really lining up a lot of growth opportunity for us as we move into next year. That'll also include China. Okay. Could you also talk a little bit about, for the quarter, the percentage of revenues that were related to recurring revenues and also new product offerings and, you know, going into 2024, if there is a potential for increases in those areas, will you have a larger percentage of recurring revenues as the total? And also, your thoughts on new products going forward, if you're gonna see that increase as a percentage of your total offerings and your efforts in that space. Thanks. Yeah, that's great, great questions. I think you're right on. You know, we at first started, you know, identifying where we were on recurring revenues, and, you know, I think it was, it's fair-- it wasn't known very well because it wasn't publicized much or even measured very well here. But we had found that we're over 35% on the recurring revenue side. And clearly, that's an area where you see the new products coming out and the new service offerings that are coming out, they are designed to not just sell new product at capital purchases, but they tend to come with consumables, services, recurring revenues. So, you know, I see an opportunity here for us to move that number from 35% well higher, you know, into the mid-40s or maybe better. That would be my longer term, the longer-term target. But with each of these new products coming out, there is a, a service and a consumable and a recurring component to it. NPI, you know, like, NPI is the lifeblood of a company like this, and technology is critical for us. So that's why you see, you know, in spite of, you know, the issues that we've all had to go through, you know, we've been working hard to keep our costs down so that we can continue to put the investment where it really is needed for a company, a technology company that's expecting to really grow, and that's a new product development. You'll see that, you know, right there in front of you at SfN this year with Society for Neuroscience. You know, we have to keep investing in these areas, and I expect, you know. I certainly expect a fairly substantial, you know, percentage of our new business to be driven by these new products. Okay, I guess just one other question then. There's been a lot of weakness in the space overall, not just you seeing some weakness in China, but some of the bigger players. Kind of in light of that weakness, are there opportunities you're starting to see out there, maybe smaller opportunities, whether it's product lines or maybe a smaller private company that might make sense for you going forward as far as, if not an acquisition opportunity, maybe a partnering opportunity or just buying a product line? Is that something you're starting to see in the space? Thank you. Yeah, that's a great question. It's certainly something that we're very interested in. You know, it took us a little while, and, you know, I was very, very public about, "Look, we're not gonna make significant structural changes or M&A type work until we finish getting our act together." And I feel like this is the year that we finished getting our act together. So we have been starting to look at where, first of all, what kind of opportunities are out there, but even more importantly, where are the places that we would make the investment to accelerate some of our new areas? We're gonna continue to invest heavily in what I call the things that really drive the ability of the pharma to meet the needs of the business, the base business. That's things like our Ponemah software, telemetry. Those are core businesses, and we're gonna continue to build on that. And those we expect to see, you know, growing at a nice clip, you know, at or above market. But the new areas, though, and when you look at bioproduction and you look at some of what we're doing in advanced cell testing with organoids and new advancements there, those are two areas that we definitely want to accelerate. So those would be two areas that we would be looking to potentially, you know, either there's maybe some licensing, some acquisition activity there for acceleration or maybe even some kind of a teaming environment that might make sense if there's something that we feel we just can't get to, given all the opportunities we have in our portfolio to invest. But definitely there's opportunity there, and as with our capital structure being in much better shape at the end of the year here, we get to Q1, you know, we'll be looking a little harder at, you know, where and what might be available to help us accelerate at least those two areas. Okay. Thank you. Thank you, Frank. Thank you. Once again, if you have a question, please press star one one on your telephone. This does conclude the question and answer session of today's program. I'd like to hand the program back to Jim Green for any further remarks. Thank you, Jonathan. Thank you all for joining us. This ends today's presentation. We hope you'll join us in the new year, for our year-end report, and that'll be sometime in the February, early March timeframe. Thank you very much. This ends the presentation. Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.